Clinical Trials

PSMA Imaging with 18F-DCFPyL PET/CT To Allow for Improved Identification of Prostate Cancer After Surgery

18F-DCFPyL is a novel low-molecular weight PET imaging agent which was developed to target prostate cancer cells which overexpress a protein known as PSMA (prostate specific membrane antigen). In an attempt to aid clinicians in managing patients with a PSA-only recurrence after radical prostatectomy we are investigating the accuracy of 18F-DCFPyL PET/CT in this clinical context. With this information, physicians have been able to customize treatment plans for these patients.

PI: Kenneth Pienta, MD

Contact Name: Narineh Abrahamian
Phone: 443-287-7790

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved. Disclaimer
Email: | 600 North Wolfe Street, Baltimore, Maryland 21287

urology second opinion urology second opinion